ロード中...
Nanoformulation of Talazoparib Delays Tumor Progression and Ascites Formation in a Late Stage Cancer Model
Talazoparib, a potent PARP inhibitor, induces synthetic lethality in BRCA-deficient cancers making it an attractive candidate for ovarian cancer treatment. However, its potency lends itself to side effects associated more closely with traditional chemotherapeutics than other clinically approved PARP...
保存先:
| 出版年: | Front Oncol |
|---|---|
| 主要な著者: | , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Frontiers Media S.A.
2019
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6524318/ https://ncbi.nlm.nih.gov/pubmed/31134152 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2019.00353 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|